DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial

Information source: Academic and Community Cancer Research United
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Minocycline (Drug); Placebo (Drug)

Phase: Phase 0

Status: Active, not recruiting

Sponsored by: Academic and Community Cancer Research United

Official(s) and/or principal investigator(s):
Charles Loprinzi, M.D., Study Chair, Affiliation: Mayo Clinic

Summary

The purpose of this study is to compare the effects, good and/or bad, of minocycline with placebo (an inactive agent) on symptoms caused by paclitaxel. In this study, the participant will get the minocycline or a placebo starting on the morning of the first dose of chemotherapy and continuing twice a day until a week after chemotherapy is finished.

Clinical Details

Official title: Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial

Study design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care

Primary outcome: Effectiveness of minocycline in paclitaxel-induced peripheral neuropathy as assessed by Quality of Life Questionnaires

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Ability to complete questionnaires by themselves or with assistance

- Planned paclitaxel at a dose of 80 mg/m2 I. V. given, in the adjuvant breast cancer

(postoperative or neo-adjuvant) setting, every week for a planned course of 12 weeks without any other concurrent cytotoxic chemotherapy (trastuzumab and/or other antibody and/or small molecule treatment is allowed, except for PARP inhibitors).

- Life expectancy >6 months

- ECOG performance status 0 or 1. (Form is available on the ACCRU web site

https://www. accru. org/accru/forms/NonProtocolSpecificForms/index. html)

- Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for

women of childbearing potential only (determined per clinician discretion). Exclusion Criteria:

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate

contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects

- Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause.

- History of allergic or other adverse reactions to minocycline

- Prior exposure to neurotoxic chemotherapy.

- Diagnosis of fibromyalgia.

- Current or planned use of methoxyflurane, oral contraceptives, isotretinoin,

penicillin, or ergot alkaloids

Locations and Contacts

Palchak David MD, Pismo Beach, California 93449, United States

Illinois Cancer Care, PC, Peoria, Illinois 61615, United States

Carle Cancer Center, Urbana, Illinois 61801, United States

Iowa Oncology Research Association CCOP, Des Moines, Iowa 50309, United States

Siouxland Hematology - Oncology Associates, LLP, Sioux City, Iowa 51101, United States

Michigan Cancer Research Consortium Community Clinical Oncology Program, Ann Arbor, Michigan 48106, United States

Mayo Clinic, Rochester, Minnesota 55905, United States

Coborn Cancer Center / CentraCare Clinic, St. Cloud, Minnesota 56303, United States

Metro-Minnesota Community Clinical Oncology Program (CCOP), St. Louis Park, Minnesota 55426, United States

Missouri Valley Cancer Consortium, Omaha, Nebraska 68106, United States

Hematology Oncology Associates of Central New York PC, East Syracuse, New York 13057, United States

Novant Health Presbyterian Medical Center - SECCC, Charlotte, North Carolina 28204, United States

Duke University Medical Center, Durham, North Carolina 27710, United States

Margaret R. Pardee Mem. Hospital - SECCC, Hendersonville, North Carolina 28791, United States

Novant Health Forsyth Medical Center - SECCC, Winston-Salem, North Carolina 27103, United States

Altru Cancer Center, Grand Forks, North Dakota 58201, United States

Women and Infants Hospital, Providence, Rhode Island 02905, United States

AnMed Health - SECCC, Anderson, South Carolina 29621, United States

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin 54449, United States

Additional Information

Starting date: November 2014
Last updated: July 22, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017